2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
1
2021 
ESG REPORT

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
2					
					
		
						
	
	
									
TABLE OF CONTENTS
3  Mission statement
4  Letter from Chairman and CEO
5  2021 highlights
6  Business overview
7 Taking care of the people we serve 
8  Improving quality of life with Cologuard®
9  Everett's story
10 About the Oncotype DX Breast Recurrence Score® 
11  Deepa's story 
12 COVID-19 response 
13 Key sustainability focus areas
14 Human Capital 
15  Satisfaction & engagement
16  Compensation & benefits
18  Career development
21  Inclusion & diversity
23  Occupational health & safety
26 Community Engagement 
27 Community partnerships 
29 Business Ethics 
30  Compliance programs
31   Integrity Alertline
32  Cybersecurity & data protection
33  Supplier management
33  Human rights
34  Board oversight
35  Addressing shareholder feedback 
37  Clincal research	
			
				
					
	
		
	
40 Product Quality 
41  Quality management system
44 Corrective & preventive action
45  Access to Health Care 
46  Access to tests
47  PreventionGenetics
48  Power of earlier detection
51  Environmental Stewardship 
52  Greenhouse gas emissions
52  Energy management
54  Water management
54  Waste management
55  Appendix 
56  Sustainability Accounting 
       Standards Board (SASB) Index 
60  Task Force on Climate-Related 
       Financial Disclosures (TCFD) Index
NOTE TO READERS
Our 2021 ESG report covers our process for, and progress in, 
addressing environmental, social, and governance topics that 
are relevant to Exact Sciences and our stakeholders. 
This report covers 2021 information primarily for our U.S. 
operations, which includes 97% of our employees, and 
has been informed by the standards established by the 
Sustainability Accounting Standards Board (SASB). Our 
disclosure against the SASB standards is provided in the 
appendix of this report.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
3
We aim to eradicate cancer and 
the suffering it causes through
tests that help prevent cancer,
detect it earlier, and guide
treatment

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
4
LETTER FROM OUR 
CHAIRMAN AND CEO
Our mission is to eradicate cancer through tests that help prevent 
cancer, detect it earlier, and guide treatment. For most cancers, a 
diagnosis in early stages means a much better chance of survival than a 
diagnosis in late stages. Our team is developing tests that help detect 
most cancers in earlier stages, as well as recurrence of cancer before 
detectable with the most sensitive imaging. We plan to change the way 
people screen for, are diagnosed with, and treat cancer. Our core values 
of integrity, innovation, accountability, quality, and teamwork ensure we 
work toward our goal in a sustainable way.
The policies and programs described in this report are important 
components of our sustainability initiative: to facilitate cancer prevention 
and smarter cancer care. The work we do every day is aimed at 
eliminating the suffering cancer causes to create a more enduring, 
cancer-free world for future generations. The success of Exact Sciences 
would reduce the economic and social burden of cancer care around the 
world.
In this report, we highlight our key sustainability focus areas, which are:
• human capital,
• community engagement,
• business ethics,
• product quality,
• access to health care, and
• environmental stewardship.
We are committed to taking care of the patients we serve, their health 
care providers, our employees, supporting the communities in which 
we work, behaving ethically, making our services accessible broadly, 
and protecting our environment. 
We’re focused on making our current advanced cancer diagnostic tests 
– Cologuard®, Oncotype®, and Oncomap™ – and our pipeline tests – the
biggest, boldest, and highest impact opportunities in cancer diagnostics
– available to more people around the world. We have brought together a
talented team dedicated to this vision, and we achieved a lot together in
2021, including:
• testing almost 4 million people and growing Screening and Precision	
Oncology revenue by nearly 30%,
• generating over $1 billion in Cologuard revenue, the first diagnostic test
to reach that milestone,
• exceeding $500 million in Precision Oncology revenue for the first time,
• adding new tests to support hereditary cancer testing, liver cancer
surveillance, and comprehensive genomic tumor profiling for advanced
cancer, and
• producing evidence to support tests solving real patient needs.
We aim to create a sustainable company based first on having 
the best team dedicated to developing advanced tests that 
solve patient needs, proven by clinical trials with strong outcome 
evidence, a superior commercial organization, high customer 
satisfaction, and increasing revenue and profits. We aim to 
achieve profitability in 2024, with sustainable profit growth 
afterwards. The best people want to work for a company pursuing 
an audacious goal like eradicating cancer, and our sustainability 
and strong governance culture helps us attract and retain them.
Kevin Conroy

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
5
6,500+​
25,251
total GHG emissions (mtCO2e)
Great Place 
to Work​
™
54% ​
workforce gender diversity​
nearly
​4 million​
people tested​ with advanced 
cancer tests and for COVID-19
90+​
countries where we 
support patients​
4,800+ ​
hours of volunteer service​​
$8M ​
in donations and educational 
and research grants
EXACT SCIENCES AT A GLANCE IN 2021
certified for the ​3rd 
consecutive year​
employees dedicated to 
defeating cancer​
​40+​
locations globally

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
6
BUSINESS OVERVIEW	
SCREENING
Cologuard is the first and only FDA-approved, non-invasive, multi-target, stool-based colorectal cancer 
screening test. There are nearly 110 million Americans at average risk for colorectal cancer who should 
be screened regularly. Today, an estimated 46 million of them are not up to date with screening 
recommendations. 
Cologuard has helped screen more than 8 million people since it was made available and has captured 
about 5 to 10 percent of the addressable market. Our long-term goal is to help meaningfully impact 
colon cancer screening rates, eradicate this terrible disease, and capture at least 40% of the market with 
Cologuard, which equates to about $7 billion in annual revenue.
PRECISION ONCOLOGY
The Oncotype portfolio of genomic tests provides personalized insights about a patient’s tumor, allowing 
them to make treatment decisions with greater confidence. Tailoring treatments to the individualized 
biology of each patient has the potential to improve outcomes and reduce health care costs by 
eliminating unnecessary and ineffective treatments.
The landmark TAILORx and RxPONDER trials used the Oncotype DX Breast Recurrence Score® test to 
define, with precision, the individual benefit of chemotherapy and risk of recurrence for early-stage breast 
cancer patients. For men diagnosed with low-, intermediate-, and high-risk localized prostate cancer, the 
Oncotype DX Genomic Prostate Score® (GPS™) test measures the expression of certain genes in prostate 
cancer cells to help guide treatment decisions at diagnosis. We also offer two therapy selection tests, 
Oncomap™and Oncomap ExTra™, for patients with advanced or rare cancers, which utilize comprehensive 
genomic profiling panels.
55%+ 
3-year compounded
annual growth rate
$1.1B
R&D investments 
over last 3 years, 
or 26% of revenue
2024
profitability target
Note: profitability target is estimate 
for full-year adjusted EBITDA 
$1.77B 
2021 revenue
$454M
$1.49B
2018
2019
2020
2021
Screening
Precision Oncology
COVID-19 testing
$876M
$1.77B
Note: 2019 includes partial year of Precision Oncology revenue due to 
Genomic Health acquisition closing in Nov. 2019
Source: U.S. Census data; Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (2021); Exact Sciences estimates

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
7
TAKING CARE OF 
THE PEOPLE WE SERVE
We plan to change the way people screen for, are diagnosed with, and treat cancer. 
We’re focused on making our current advanced cancer diagnostic tests – 
Cologuard, Oncotype, and Oncomap – available to more people around the world.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
8
IMPROVING QUALITY OF LIFE WITH
Source: Imperiale TF et al., N Engl J Med (2014); Gagrat ZD et al., ASCO GI Cancers Symposium (2022); numbers presented here based on modeling analysis performed on Jan. 13, 2022 using point estimates of performance, CRC-
AIM Natural History version 1.0.5, and CRC-AIM Screening version 1.0.9; simulated a population of 2M individuals screened between ages 45 & 75 with mt-sDNA 1.0 every 3 years – reported results per 1M screened 
Health economic models show 
Cologuard can lead to a:​
65%​​
73%​​
reduction in colorectal ​
cancer incidence​
reduction in colorectal ​
cancer mortality
318K 
years of life are gained​
by the end of 2021, 
we screened more than ​
7.5M 
people with Cologuard​
for every 1 million patients 
screened with Cologuard​

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
9
EVERETT’S STORY
When I was born on the predominantly African American 
east side of the river in Waterloo, Iowa, and raised in the area, 
most of my family members did not live to see old age. The 
health disparities that existed then and now in my community 
are painfully evident. I have lost too many people I love to very 
treatable cancers and preventable diseases. My grandparents 
died in their 50s. My father was 57 when he died and my mother 
in her 60s. Most of my uncles passed around the same age.​
My loved ones did not get screened for cancer or have access to 
the preventive care that I do. And even though I’m now 55, and 
I should know better, I was on track to repeat my family’s health 
history. As a busy executive whose days are filled by the minute, I 
told myself that I couldn’t make the time for a colonoscopy. And 
as the years passed, I kept making excuses.​
In 2021, I became Chief Commercial Officer for Exact Sciences. 
During my first week with the company, I heard our CEO Kevin 
Conroy speak about the work we’re doing to catch cancer early 
and the difference that makes in treatment outcomes and 
quality of life. ​
That’s when it hit me: there was no excuse for 
me to avoid taking ​charge of my own health. I 
had to get screened for colorectal cancer.
My three daughters are now young adults, and my youngest 
was just a newborn when my father passed away. He missed 
so much of their lives, and I did not want to make the same 
mistake. I want my daughters to see me as an old man with 
grandkids running around — I want to have the experiences I 
missed with my parents and grandparents.
I took my wife on this cancer screening journey with me — 
she is 54 and a busy physician who had also put off getting a 
colonoscopy. We both did a home screening with Cologuard, 
a non-invasive stool test, and it couldn’t have been easier. 
Cologuard comes with a returnable kit that you leave on your 
doorstep for UPS to collect.​
Less than two weeks later, my wife and I were in our living room 
when we received our Cologuard results by email. My test came 
back negative. I breathed a sigh of relief and made plans to do 
another home screening in three years. But my wife’s test was 
positive. She quickly connected with her doctor to schedule 
a follow-up colonoscopy, a step she admitted she would have 
continued delaying if it were not for Cologuard. To say we 
are happy she did the Cologuard test is an understatement. 
During her follow-up colonoscopy, they discovered a pre-
cancerous lesions in my wife’s colon that had already grown to 4 
centimeters in size. These pre-cancerous adenomas may become 
cancer over time and are surgically removed to prevent the 
disease from ever happening.  
I was a believer in Cologuard, now I am an 
evangelist.​
I’m sharing my family’s story because there are nearly 46 million 
people who have not been screened for colorectal cancer. There 
is no better time to talk to your doctor about getting screened 
than now. But we know that having “your doctor” is not a given, 
especially in places like where I grew up. Most of my relatives 
don’t have a primary care physician — they call my wife when 
they feel sick. Doctors can be intimidating to Black people, so 
their “doctor” often ends up being the emergency room.​
One of the positive trends to emerge from the pandemic is the 
growing acceptance and reach of telemedicine, which can make 
it easier for people to consult with a doctor and get access to 
potentially life-saving screenings. I have cousins in Waterloo
who work hourly jobs, and they can’t afford to take two days off 
for a colonoscopy, which is why we’re working to expand access 
to and awareness of Cologuard.​
Colorectal cancer does not have to be a death sentence — 
catching it in a pre-cancerous stage or at stage I is completely 
different than catching it in stage IV. You might feel healthy 
and look healthy, but that does not mean you can afford to 
delay screening. My wife runs every day and is healthier than 
she was when we met in college 37 years ago, and yet her test 
was positive, and they found a pre-cancerous lesion. You can 
take control by getting screened, and you can do it from the 
convenience of your home.​
There’s too much to miss out on.​
Everett Cunningham 
Chief Commercial Officer at Exact Sciences

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
10
USING GENOMIC INFORMATION TO 
PERSONALIZE BREAST CANCER TREATMENT
*includes early-stage breast cancer patients who are postmenopausal, HR-positive (HR+), HER2-negative (HER2−), node-negative, or node-positive (1-3 nodes), with Oncotype DX Breast Recurrence Score results of 0-25;
Sources: NCCN Guidelines: Breast Cancer, version 4.2021; Albain et al. Lancet Oncol. 2010; Kalinsky et al. N Engl J Med. 2021.; Geyer et al. NPJ Breast Cancer. 2018; Sparano et al. N Engl J Med. 2018.; 
F. Andre, et al. JCO 2022.; NCCN Clinical Practice Guidelines in Oncology for Breast Cancer V. 1.2022.; Note: National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN.
About the
The Oncotype DX Breast Recurrence Score test is proven to predict the likely benefit of 
chemotherapy – as well as the risk of distant recurrence – for patients who are newly 
diagnosed with early-stage invasive breast cancer. 
It’s also the only genomic test classified as “preferred” by the National Comprehensive Cancer 
Network (NCCN®) Clinical Practice Guidelines in Oncology for breast cancer, with the highest 
level of evidence for node-negative and postmenopausal node-positive patients. 
The American Society of Clinical Oncology (ASCO®) guidelines also strongly recommend use 
of the Oncotype DX Breast Recurrence Score test in node-negative and the majority of node-
positive early-stage breast cancer patients. 
80%
1M+
Results from the independent TAILORx 
and RxPONDER trials showed
By the end of 2021, the 
Breast Recurrence Score test spared
test
of patients do not benefit 
from chemotherapy*
patients from unnecessary 
chemotherapy treatments

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
11
“All of this has allowed me to gain a 
unique perspective from being a breast 
cancer surgeon and breast cancer 
patient. Now I know what it’s like to face 
cancer. I have walked in my patients’ 
shoes.”
After her mastectomy, the pathology results showed 
that she had a 1.5 cm tumor. Deepa immediately 
knew that she would need the Oncotype Dx Breast 
Recurrence Score test. Based on her clinical features, 
Deepa guessed that she would have an Oncotype 
DX Recurrence Score of 10.
The results came back with a Recurrence Score of 
18, meaning her benefit from chemotherapy would 
be low, and she decided not to proceed with the 
therapy.
Her experience as a patient reminded her there 
are real people behind the statistics doctors give 
to patients. Deepa prioritizes calling her patients 
as soon as their results are available because she 
understands their anxiety when waiting for answers. 
Deepa makes sure her patients engage in a shared 
decision-making process about treatment and are 
empowered to ask the right questions when they 
see a medical oncologist.
DEEPA’S STORY
While on spring break with her family, Deepa 
felt pain in the right side of her chest. After a 
mammogram revealed a mass in her breast, she 
immediately got an ultrasound and biopsy. At 41, 
Deepa was diagnosed with invasive breast cancer.
Deepa was a new breast surgeon faculty member in 
Ohio. Like most patients, she was devastated by her 
diagnosis. She faced the same decisions her patients 
make – whether to get a lumpectomy or mastectomy 
and whether to use chemotherapy or not.
Dr. Deepa Halaharvi, breast cancer survivor

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
12
SUPPORTING THE 
FIGHT AGAINST COVID-19
reduction in colorectal ​
cancer incidence​
reduction in colorectal ​
cancer mortality
What started as a mission to take care of 
our employees during the early days of the 
COVID-19 pandemic quickly grew into an 
opportunity to serve our communities. More 
than 1,000 people from our R&D, lab, IT, and 
operations teams collaborated to develop, 
secure FDA emergency use authorization, 
and launch a scalable COVID-19 testing 
solution. 
By the end of 2021, 
we completed more than
3.7M 
COVID-19 tests
50 states
and delivered results to all

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
13
OUR VALUES
OUR KEY SUSTAINABILITY 
FOCUS AREAS
Sustainability is embedded within our core values 
Human Capital​
We are committed to providing safe and healthy 
work environments for our employees, where 
equal opportunity and diversity in thought, 
experience, perspective, and background are 
commonplace.
Access to Health Care​
We relentlessly pursue smarter solutions providing 
the clarity to take life-changing action earlier, and 
our goal is to make our tests easily accessible to 
patients and health care professionals.
Business Ethics​
We expect every employee to practice the 
highest standards of conduct in every business 
relationship within the company and with our 
customers, business partners, competitors, and 
the community in which they work.
Environmental Stewardship​
We are committed to operating our business 
and facilities and to producing our products in 
a manner that respects and protects human 
health and the environment.
Product Quality​
We are committed to meeting customer 
requirements and complying with applicable 
regulatory, laboratory accreditation, and quality 
management system standards.
TEAMWORK
INTEGRITY
QUALITY
INNOVATION
ACCOUNTABILITY
Community Engagement​
The grit and determination that drives our business is 
the same spirit we apply to helping our communities. 
With engaged citizens and responsible companies, we 
believe communities can find solutions to the issues 
they face and foster potential for the next generation.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
14
HUMAN CAPITAL
Our approach
We are committed to providing safe and healthy work environments 
for our employees, where equal opportunity and diversity in thought, 
experience, perspective, and background are commonplace. 
We are taking action through several social initiatives to 
foster employee loyalty. ​
These actions include:
•	 Making Exact Sciences a Great Place to Work​
•	 Enhancing our industry-leading compensation and benefits​
•	 Offering best-in-class wellness benefits​
•	 Expanding leadership coaching and development programs​
•	 Promoting inclusion and diversity​
•	 Creating a safe place to work

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
15
SATISFACTION & ENGAGEMENT
RESULTS & RECOGNITION
Our approach
We believe in creating an employee experience 
that helps people identify meaning and purpose in 
their work, feel valued for their contributions, and 
have a sense of belonging. Measurement is a critical 
step in understanding our employees’ experience 
and identifying areas of opportunity. Results from 
anonymous employee surveys guide managers 
in developing action plans to optimize team 
engagement and performance. 
Measuring engagement
We conduct an annual, anonymous employee survey 
administered by Gallup to help measure the overall 
engagement and satisfaction of our team. In 2021, 85% 
of employees participated in the Gallup survey. We 
also conduct several ‘pulse’ surveys throughout the 
year to ensure we are sustaining a motivating, fun, and 
rewarding workplace culture. 
Our action plan
We continue investing in people and tools to address 
employee feedback. We believe this will help maintain 
a positive culture and improve employee loyalty.
We have consistently achieved high employee 
engagement scores by investing in our 
communities and internal talent. Exact Sciences 
was Great Place to Work certified for the third year 
in a row in 2021, with 88% of survey participants 
saying that Exact Sciences is a great place to work 
(compared to 90% in 2020 and 92% in 2019).
57%
88%
Exact Sciences
Typical company
Source: Great Place to Work 2021 Employee Engagement Study
Best Workplaces in Health 
Care & Biopharma™ 2021
Best Workplaces for 
Millennials™ 2021
88%
​
of employees at Exact Sciences say it is a great 
place to work compared to 57% of employees at a 
typical U.S.-based company.
94%
93%
93%
92%
92%
I’m proud to tell others I work here
I feel good about the ways we 
contribute to the community
When you join the company, 
you are made to feel welcome
Our facilities contribute to a 
good working environment
I am able to take time off from
work when I think it’s necessary

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
16
COMPENSATION & BENEFITS
Our approach
We are committed to improving and maintaining the health and well-being of our employees. Our comprehensive total rewards program provides industry-leading 
compensation and benefits to inspire a sense of ownership in our company’s success and meet the needs of our diverse, global workforce. We launched new time-
away policies and core benefits in 2021 to enhance our nationally-recognized wellness offerings. 
FINANCIAL BENEFITS
•	
Restricted Stock Units (RSU) 
[new hire & annual awards]
•	
401(k) retirement plan with 
discretionary company match
•	
Employee Stock Purchase Plan 
(ESPP)
•	
Deferred compensation plan
•	
Tuition reimbursement program
•	
Short- and long-term disability
•	
Life and AD&D insurance
•	
Business travel accident
•	
Commuter benefits
•	
Adoption assistance
•	
Charitable donation match 
program
•	
Prepaid legal services
•	
Pet insurance discounts
•	
Auto & home insurance discounts
HEALTH BENEFITS 
•	
Medical & prescription coverage
•	
Dental plan options 
•	
Vision plan options 
•	
Health Savings Account (HSA)
with employee and employer 
contributions
•	
Flexible Spending Accounts (FSA)
•	
Accident and critical illness 
benefits
WELL-BEING BENEFITS
•	
Annual Health Risk Assessment 
(HRA) program
•	
Employee Assistance Program 
(EAP) available 24/7
•	
Wellness points program
•	
Fitness reimbursement program
•	
Fitness classes
•	
Mentor program
•	
Care.com premium membership
•	
Tobacco cessation support
•	
Blood drives
•	
Flu shot clinics
•	
Onsite dining (at select locations)
•	
Mother’s & well-being rooms
•	
Milk Stork for traveling 
breastfeeding moms
WORK LIFE BALANCE
•	
Paid vacation days
•	
Sick time off
•	
Volunteer time off
•	
Parental leave
•	
Family caregiver leave
•	
Personal leave
•	
Bereavement time off
•	
Jury or witness duty time off
•	
Time off to vote
•	
Military leave
•	
FMLA & other federal, state, 
municipal leaves
•	
Flexible working arrangements, 
including hybrid or remote options
Eligibility for certain benefits may differ based on factors such as full-time or part-time status, hours worked, length of service, work location, regulatory requirements, etc.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
17
WELLNESS PROGRAMS & RECOGNITION
Our approach
The purpose of our wellness programs is to positively impact the mental, physical, 
social, and financial well-being of our employees through inclusive programming 
rooted in empathy, compassion, and trust. Consistent with Exact Sciences’ core values 
of integrity, teamwork, accountability, innovation, and quality, we provide a unique, 
best-in-class experience that is authentic and collaborative. The wellness team at Exact 
Sciences works hard to foster a culture of care and compassion to help our employees 
and communities live happy, healthy, and full lives. 
Wellness awards
Exact Sciences was named among America’s Healthiest 
Companies in 2021 by the Wellness Council of America 
(WELCOA), a nationally respected resource for healthy, high-
performing workplaces. We received the Platinum Well 
Workplace Award, the highest award given by WELCOA, 
reflecting our leadership and innovation in workplace health. 
We received Gold level recognition from the American Heart 
Association’s Workplace Health Achievement Index, which 
recognizes companies that implement quality workplace 
health programs and display a culture of best health 
practices.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
18
CAREER DEVELOPMENT & 
FEEDBACK
Our approach
One of the most important aspects of career development is receiving feedback. 
We utilize a variety of tools to facilitate developmental feedback and career 
progression. 
Annual review process
Our annual review process, referred to as the Exact Journey, begins with 
collaborative goal setting at the beginning of the year and ends with an annual 
performance discussion. To set goals, employees work with their direct manager 
to connect the priorities of the company to their specific duties. Once goals are 
set, employees and their managers have quarterly check-ins. This involves ongoing 
discussions assessing progress toward individual goals and key engagement 
drivers, which vary by quarter and business priorities. At the end of the year, 
each employee completes a self-assessment, reflecting on their progress and 
achievements, and defining what they view as their strengths, aspirations, and 
development opportunities. Their manager then completes an assessment, which 
is followed by an engaging discussion focused on personal growth and teamwork. 
The goal-setting process restarts each year. The program applies to all full-time and 
part-time Exact Sciences employees who perform work responsibilities at Exact 
Sciences.
We also offer a variety of assessments, such as a leadership 360 survey, to gain 
insights that support development. 
Thanks, in large part, to our training and development investments, we filled 34% 
of our open positions with internal candidates in 2021. In the last quarter of 2021, 
that rate was 39%.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
19
LEARNING & DEVELOPMENT PROGRAMS
Employee training programs
We developed and implemented a comprehensive employee training program, 
governed by Exact Sciences’ Employee Training Policy. The program applies 
to all Exact Sciences employees, including full-time, part-time, and temporary 
employees who perform work responsibilities at Exact Sciences.
Senior leadership, in conjunction with human resources, is responsible for ensuring 
that all employees, including contractors and consultants, have the appropriate 
education, training, competency, and credentials.
Our training and development team provides technical training to our operational 
employees for roles such as specimen processing and customer service. More 
than 5,700 in-person and 19,800 online courses were completed by our operations 
team members during 2021. We also have a commercial effectiveness team that 
is responsible for ensuring employees in sales promote Exact Sciences products 
to health care professionals accurately and effectively. Throughout the year, new 
and experienced members of our commercial team completed more than 100,000 
hours of live training.
Our organizational development and functional training teams create 
opportunities for personal growth, professional development, and career mobility. 
From facilitated workshops and podcasts, to eLearning modules and succession 
planning, we have invested in the internal capabilities to meet our employees at 
any stage of their career growth and development. Many of these courses can be 
completed through our online Learning Universe platform.
Leadership training programs
We expect our leaders to build the best teams, have a clear vision, and 
demonstrate humility and will. To support the ongoing development of our 
leaders, we continue to expand our one-on-one leadership team, and group 
coaching opportunities. We partnered with 57 leadership teams on their own 
team development. Over the past year, we added Strategic Planning, Coaching 
Skills for Leaders, A Leader’s Role in Inclusion, and Leadership Connections 
webinars.
We also hosted a Leadership Connect Summit for our senior leaders to network, 
develop and refine their leadership capabilities, as well as learn more about 
various areas of our business. A series of webcasts were created to cascade the 
key learnings from the summit to all employees in the company.
Education & professional development reimbursement
Exact Sciences offers financial support to approved employees who participate 
in externally-sponsored educational and professional development courses 
that meet specific criteria. We contributed over $800,000 in education and 
professional development reimbursement to enhance employees’ skills and 
knowledge related to our business during 2021.
In 2021, more than 886,000 courses were completed on Learning Universe by 
employees around the world.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
20
INTERNSHIP & DEVELOPMENT PROGRAMS
Internship program
Our paid internship program introduces Exact Sciences’ mission-driven culture 
to young professionals. A program that started with 2 interns in 2013 now 
introduces more than 120 young professionals from across the country to Exact 
Sciences each year.  
 
Our internship program includes a “Career Exploration Pathways” program so 
interns not only gain experience in their own team or functional area, but also 
learn from other departments and functions. Summer interns also take part in 
team-based projects and present their ideas to company leadership. This aspect 
of the program is designed to provide real-world experience and help students 
explore the breadth of careers in the health care industry before they graduate 
from college. 
Apprenticeship program
In 2021, Exact Sciences started its first State of Wisconsin registered apprenticeship 
program to invest in our future talent needs and improve access to economic 
opportunity. The apprenticeship program includes facilities maintenance 
opportunities and a partnership with the State of Wisconsin Department 
of Workforce Development and Madison College to support the program 
infrastructure.
Mentorship program
Exact Sciences launched an organization-wide mentoring program in 2021. Over 
20% of our employees enrolled in the program, resulting in more than 1,000 
hours of mentoring. The mentoring program connected employees across work 
functions and locations globally.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
21
Our approach
We believe creating a diverse and inclusive culture across all levels of our 
organization is necessary to support our core values. We are committed to 
approaching our inclusion journey with purpose and empathy. Our talent 
strategy and inclusion team is responsible for developing and implementing our 
inclusion and diversity programs with oversight by our EVP, Human Resources.
We took many actions in 2021 to: 
These actions include: 
•	
Expanding and promoting inclusion and diversity training programs
•	
Increasing access to employment opportunities for diverse populations
•	
Creating campaigns to improve awareness and access to cancer screenings
among diverse populations
•	
Providing $480,000 to 28 organizations supporting gender and racial equity
INCLUSION & DIVERSITY
BUILD A BETTER EXACT SCIENCES,
DRIVE HEALTH EQUITY, AND
CREATE STRONG COMMUNITIES.
Gender diversity
Board of Directors
Leadership positions
(Director level and above)
Workforce
44%
42%
54%
56%
58%
46%
Women	         Men
Ethnic/racial diversity
Board of Directors
Leadership positions
(Director level and above)
Workforce
89%
81%
72%
11%
19%
28%
White	
  Non-white

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
22
Respectful workplace training
Our inclusion training is open to all employees, offering an opportunity to learn in 
a supportive and safe space where we can build empathy and create a sense of 
belonging. In 2021, more than 2,000 of our employees participated in a Respectful 
Workplace course.
Courses offered: 
Facilitated discussions on racism 
Facilitated discussions on unconscious bias
Creating an inclusive culture
Understanding gender, gender expression, and gender identity
We also launched a training course called, “A Leader’s Role in Inclusion.” We 
thoughtfully designed this course to provide leaders the chance to connect with 
peers, uncover common challenges, and reflect on their responsibilities in creating an 
inclusive climate for their teams.
INCLUSION & DIVERSITY 
TRAINING PROGRAMS
STORIES ABOUT US
We created a podcast series, “The Respectful 
Workplace: Stories About Us” to provide 
a platform for employees to share their 
unique inclusion experiences. Our 35 podcast 
episodes feature Exact Sciences employees 
and were listened to more than 3,000 times 
during 2021.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
23
Our approach
We are committed to providing safe and healthy working conditions for our employees, contractors, and visitors, 
as well as conducting all operations and activities in a manner that protects human health and quality of life. Our 
Health and Safety Policy is embedded in our Code of Business Conduct and Ethics and applies to all of our global 
locations.
OH&S oversight 
We have dedicated OH&S resources that work closely with all business units and functions to establish and 
implement health and safety programs and policies. To ensure accountability and involvement, we established 
local safety committees comprised of managers, supervisors, and employees, focused on safety culture 
and compliance. These committees meet frequently to drive health and safety awareness and continuous 
improvement. Specific areas of committee responsibility include:
•	
Hazard inspections
•	
Risk assessments
•	
Safety metric and incident reviews
•	
Safety-related engagement activities
OH&S Management System
Exact Sciences has developed and implemented a company-wide Health and Safety Management System to 
ensure compliance with all health and safety programs, policies, procedures, and laws.  As part of our OH&S 
Management System, we undertake the following on a regular basis:
•	
Compliance audits	
• Internal audits covering federal, state, and regional regulations	
• Internal inspections of clinical laboratories
•	
Risk assessments for people, property, and environment
•	
Employee training
OCCUPATIONAL 
HEALTH & SAFETY (OH&S)

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
24
OCCUPATIONAL HEALTH & 
SAFETY TRAINING & METRICS
Health & safety training
Eliminating injuries and focusing on the well-being of our employees makes us more competitive by 
increasing productivity, enhancing employee engagement, improving retention, and reducing health care 
costs. We provide tools and training to help achieve our goal of zero injuries, incidents, and fatalities. 
All employees, including part-time employees and contractors, receive training on:
•	
Health & safety management
•	
Incident reporting
•	
Safe use of equipment
•	
Chemical safety
•	
Electrical safety
•	
Personal protective equipment (PPE)
•	
Fire safety
•	
Emergency response
•	
Blood-borne pathogens safety
•	
Ergonomics
•	
Safety committees/engagement opportunities
Additional training is provided for specific roles including, but not limited to, annual training for all 
employees who may:
•	
Handle hazardous waste
•	
Perform equipment maintenance – training includes an annual review of all energy control procedures
•	
Drive a forklift or other powered industrial truck
•	
Be exposed to high voltages of electricity – training includes annual electrical safe work practices
training
•	
Perform work that creates sparks and open flames
•	
Perform work in confined spaces
•	
Be exposed to fall hazards
•	
Handle, store, and dispose of dry ice
•	
Work with hazardous chemicals and/or blood or other bodily fluids
OCCUPATIONAL HEALTH & SAFETY (OH&S) METRICS
Total recordable
incident rate*
Days away 
restricted time
2019
2020
2021
2019
2020
2021
Total 
0.62
0.51
0.62
0.45
0.41
0.47
Lab
1.29
1.03
1.26
0.32
0.96
0.96
Other
0.41
0.05
0.2
0.17
0.05
0.12
*per 200,000 hours worked
All work-related near misses, injuries, or illnesses, however slight, must be 
reported as soon as reasonably possible to the department leader. We deeply 
regret to report that one employee fatality occurred during 2021 in a road 
accident while traveling to visit a customer. Our employees’ safety is our top 
priority, and we are evaluating ways to enhance our safety programs going 
forward. No employee or contractor fatalities occurred during 2019 or 2020.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
25
Chemical safety
Exact Sciences has developed and implemented a 
chemical hygiene plan for use in laboratories. The 
plan includes procedures for: 
•	
Determining employee exposure
•	
Controlling chemical exposure — this includes
exploring opportunities to substitute traditionally
used chemicals with chemicals that are less
hazardous, and reducing the amount of chemicals
needed for a lab experiment through microscaling
All new employees must complete training on the 
chemical hygiene plan, and affected employees must 
review the chemical hygiene plan on an annual basis.
Hazard communication
Exact Sciences has developed and implemented a 
hazard communication program. The program was 
developed to ensure that the hazards of all chemicals 
used at the facility are evaluated, and that information 
concerning their hazards is transmitted to employees. 
All personnel are trained on chemical exposures 
(actual or potential), related risks at the facility, and the 
appropriate protective measures available to them. 
All employees who work with hazardous chemicals 
must complete annual training on the hazard 
communication program.
Emergency preparedness
Exact Sciences has developed and maintains a 
dedicated emergency preparedness program, which 
outlines the steps and guidelines for handling any site 
emergency. Emergency preparedness procedures are 
described in the Environmental, Health, and Safety 
Handbook, and include procedures to follow in the 
event of: 
•	
Chemical spills
•	
Slips, trips, and falls
•	
Exposure to bloodborne pathogens
•	
Electrical safety risks
•	
Evacuation
We have developed and implemented a medical 
responder program, which includes performing drills 
and testing our emergency notification system. 
We have appointed evacuation sweepers and 
coordinators, who receive regular training on 
emergency preparedness procedures. 
OCCUPATIONAL HEALTH & SAFETY PROGRAMS

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
26
COMMUNITY 
ENGAGEMENT
The grit and determination that drives our business is the same spirit we 
apply to helping our communities. With engaged citizens and responsible 
companies, we believe communities can find solutions to the issues they 
face and foster potential for the next generation.
Our approach
Being part of the community means getting involved. Exact Sciences offers 
employees paid volunteer time off to work with nonprofit organizations of 
their choice. We support individuals and organizations making a positive 
difference by advancing cancer care, creating economic opportunity, and 
addressing health equity.​
Highlights from our 2021 community involvement include:
•	
Partnering with local organizations to create career opportunities for
diverse populations
•	
Contributing over 4,800 volunteer hours through paid volunteer time off
•	
Raising more than $1.3 million during our annual United Way giving
campaign

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
27
COMMUNITY PARTNERSHIPS
United Way campaign
In 2021, we continued our annual tradition of 
holding a workplace giving campaign through
United Way. During the campaign, employees 
donated more than $650,000. Exact Sciences 
matched each dollar donated by employees, 
which led to the team raising $1.3 million to 
support chapters around the world. To recognize 
the generosity of our employees, Exact Sciences 
received the United Way of Dane County 
People’s Choice Award.
Goodman Community Center
We partnered with Goodman’s TeenWorks 
program in Madison to share insights into 
employee journeys and careers at Exact 
Sciences. Our culinary team hosted a panel for 
students interested in culinary careers.
Maydm
We partnered with Maydm, a Madison-based 
community organization focused on educating 
girls and youth of color about STEM career 
opportunities. Last year, we employed 4 high 
school summer interns, helping them gain real 
world experience in data science, IT infrastructure, 
and engineering.​
Employee sponsorship
Our corporate giving program allows employees 
to request funds for community organizations 
they are passionate about. In 2021, we provided 
25 unique U.S. nonprofit organizations with a 
corporate gift through this program. ​
Posse Foundation
Exact Sciences hosted two Posse Foundation 
career fairs in 2021, introducing first-generation 
college students and college students of color from 
Wisconsin and Illinois to Exact Sciences internship 
and career opportunities.
During 2021, 
employees contributed
and Exact Sciences contributed
4,800+
​
$8M​​
volunteer hours to
170 organizations
in donations and educational 
and research grants

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
28
CREATING ECONOMIC OPPORTUNITIES 
FOR DIVERSE TALENT
Our partnership with the Urban League of Greater Madison (ULGM) 
Exact Sciences continued its partnership with the Urban League of Greater 
Madison (Wisconsin), enrolling 66 trainees in the ULGM Career Academy 
throughout 2021. Nearly 200 trainees have participated in the program since it 
was launched in 2018, with 90% of participants receiving job offers.
Our partnership with the ULGM was highlighted to the U.S. Department of 
Commerce, where senior leadership from Exact Sciences and ULGM held a 
briefing on the program. The program was well received with both parties 
agreeing to work toward potential future engagement.
We also committed $500,000 to the ULGM’s $25.3 million Black Business Hub 
project and plan to lease space inside the building once it’s constructed.
Sketch of the Black Business Hub located on South Park St. in Madison, WI
“Exact Sciences and the Urban League of Greater Madison share 
a goal to empower individuals and create positive economic 
change. Together, our organizations operate a job training 
academy that helps upskill job seekers and support career 
transitions. We are excited to build upon this program with 
Exact Sciences as a founding tenant of the Urban League’s 
Black Business Hub, scheduled to open in 2023.” 
– Dr. Ruben Anthony, Urban League CEO

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
29
BUSINESS ETHICS
Our approach
We believe that conducting business ethically is critical to our 
near- and long-term success. Quality, integrity, accountability, 
innovation, and teamwork are the foundation upon which we 
build our reputation and our competitive excellence. 
We expect every director, officer, and employee to practice the 
highest standards of conduct in every business relationship 
within the company and with our customers, business partners, 
competitors, and the communities in which we work. 
Our culture and policies are designed to help employees do 
what is right for our business, the environment, and society.
Code of Business Conduct and Ethics
Code of Conduct on Interactions with Health Care Professionals

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
30
COMPLIANCE PROGRAMS
RESPONSIBLE INTERACTIONS WITH 
HEALTH CARE PROFESSIONALS
Exact Sciences has created and implemented a comprehensive 
corporate compliance program to maintain the highest 
professional and ethical standards. 
The Exact Sciences compliance organization, led by the 
company’s Chief Compliance Counsel and supported by 
internal audit and legal, ensures that regular reviews and audits 
are performed across our organization to assess compliance 
with our Code of Business Conduct and Ethics and all related 
ethics policies. Our Chief Compliance Counsel is responsible 
for implementation and compliance with our bribery and 
corruption program. We have an active Compliance Committee, 
comprised of senior officers and cross-functional leaders. 
The Committee meets quarterly, receives updates on various 
compliance and privacy projects and matters, and maintains 
communication with personnel at all levels of the company. The 
Compliance Committee updates the board quarterly, with a 
more in-depth presentation done annually.
We conduct various monitoring and auditing activities across all 
business operations in partnership with internal audit, finance, 
and legal. We use technology and automated tools to monitor 
and report on compliance matters.
All Exact Sciences employees receive training on the Code 
of Business Conduct and Ethics, as well as other legal and 
compliance policies and processes when they join the company. 
We expect our employees to read, understand, and abide by the 
requirements in the Code to ensure ethical business practices 
and compliance throughout our organization. Additionally, Exact 
Sciences’ program includes measures to ensure compliance 
with all applicable laws prohibiting foreign public and private 
bribery or corruption.
In addition to requiring that all interactions with health care 
professionals and other customers comply with applicable 
laws, we seek to ensure that our interactions with health care 
professionals consistently meet or exceed industry guidelines. 
We ensure the integrity of our promotional materials by 
following a robust internal review process grounded in the 
principles of clear and truthful communications.
Exact Sciences voluntarily complies with and fully supports 
the Advanced Medical Technology Association (AdvaMed) 
“Code on Interactions with U.S. Health Care Professionals.” 
The AdvaMed Code was developed to address interactions 
with health care professionals that are specific to the medical 
technology industry. The Code provides firm guidance on such 
interactions including the use of promotional materials, grants 
and consulting arrangements, meals and entertainment, 
continuing medical education, clinical practice guidelines, and 
sales and marketing training for company representatives. 
Exact Sciences adheres to all the provisions of the Code. 
The Chief Compliance Counsel is responsible for developing, 
operating, and monitoring compliance with our Code of 
Conduct on Interactions with Health Care Professionals. The 
Chief Compliance Counsel reports to the Board of Directors 
and the Chief Legal Officer, who reports to Chief Executive 
Officer and to the Board.
Employees involved in sales and marketing receive regular 
compliance training on the laws, regulations, and codes that 
govern interactions with physicians and other customers, on 
the promotion of our products, and on our Code of Conduct on 
Interactions with Health Care Professionals.
Exact Sciences’ compliance program provides training on a wide 
variety of topics. All employees receive annual training on anti-bribery 
and anti-corruption, conflicts of interest, anti-harassment, data 
protection and privacy, and other policies and procedures that outline 
how they are expected to conduct their day-to-day responsibilities.
Exact Sciences’ Compliance Committee supports legal and ethical 
conduct throughout the company. Employees have an obligation 
to report any conduct that they, in good faith, believe violates laws, 
corporate policies, and/or the Code of Ethics on Interactions with U.S. 
Health Care Professionals. There are various avenues available to seek 
advice on ethical behavior and to report concerns related to violations 
of such behavior.
Exact Sciences is committed to exchanging information with health 
care professionals in an ethical and responsible way, keeping the best 
interests of patients at the forefront. The company has established 
mandatory standards that all staff members, consultants, contract 
workers, and temporary staff must follow when interacting with health 
care professionals and other customers. See our Code of Conduct on 
Interactions with Health Care Professionals.
Exact Sciences maintains collaborative relationships with health care 
professionals, where appropriate, in order to:
•	
Develop new products
•	
Determine appropriate and beneficial uses for products
•	
Support medical research and other educational, scientific, and
charitable activities
•	
Provide health care professionals and the public with information
regarding the benefits and risks of its products
•	
Obtain feedback and advice about its products from medical
experts

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
31
REPORTING A CONCERN
Exact Sciences has established various ways for individuals to raise concerns regarding the conduct of company 
officials or ethical, legal, or other issues related to the way the company is conducting its business. One avenue 
for raising such issues, the Integrity Alertline, is described below. Additional avenues are identified in our Code of 
Business Conduct and Ethics.​
Exact Sciences takes all reports to the Integrity Alertline seriously and has a process in place to handle all reports on a 
case-by-case basis.​
​The Exact Sciences Integrity Alertline is available to report any conduct or action which is, or may appear, inconsistent 
with applicable law, Exact Sciences policies, the Code of Business Conduct and Ethics, or Exact Sciences’ values. 
The Alertline provides a means of filing a report anonymously (where permitted by applicable law) 24 hours a day, 
seven days a week, to a third-party service provider ensuring a caller’s confidentiality. Exact Sciences will not retaliate 
against any employee who reports a complaint or concern in good faith. The Alertline is available to all employees, 
contractors, and third parties, who can dial the Alertline directly at directly at 1-800-93-ALERT or go to 
exactsciences.alertline.com to enter their concern through a web portal.​ A concern can be reported or a question 
can be asked in any language via the telephone line by asking for a translator. The webform is available in multiple 
languages. Calls are not recorded and IP addresses are not retained.​
Employees are required to complete training on our Code of Conduct during new hire and annual refresher training. 
These trainings include reference to obligation to raise concerns, including the process to use the Alertline, as well as 
our non-retaliation policy. Information about the Alertline is available in multiple locations on our company intranet.
​Exact Sciences maintains standard procedures for escalating and investigating whistleblower concerns. Such 
investigations are handled in a manner that is as confidential as possible under the circumstances. The company 
determines if misconduct has occurred and takes the action it decides is appropriate.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
32​
CYBERSECURITY & DATA 
PROTECTION RISK MANAGEMENT
Protecting the privacy of our patients’ and employees’ information and the security of our systems 
and networks has long been and will continue to be a priority for Exact Sciences and our Board 
of Directors. We have technical, administrative, and physical safeguards in place to help protect 
against unauthorized access to, use, or disclosure of patient and employee information and data 
we collect and store. In addition, our comprehensive information security program includes, 
among other aspects, vulnerability management, antivirus and malware protection, file integrity 
monitoring, encryption, and access control. 
Consistent with our Board of Directors’ risk management and oversight structure, our Audit and 
Finance Committee has primary responsibility for overseeing our risk management practices, 
programs, policies, and procedures related to data privacy, data protection, and network security. 
Management provides our Audit and Finance Committee and our Board of Directors with updates 
about cybersecurity practices, programs, policies, and procedures and the status of projects 
designed to strengthen internal cybersecurity and data protection. Our Board of Directors and our 
Audit and Finance Committee also discuss potential cybersecurity and data protection threats. 
U.S. employees receive Health Insurance Portability and Accountability Act (HIPAA) training 
during new hire training and on an annual basis via our online Learning Universe platform. 
International employees and U.S. employees that handle EU personal data receive General Data 
Protection Regulation (GDPR) training in Learning Universe during new hire and annual refresher 
training. U.S. employees that do not directly handle such data receive training on general global 
privacy and data protection concepts. All new hires receive California Consumer Privacy Act 
(CCPA) training upon hire and annual training is reserved for those employees that are involved in 
handling inquiries or compliance with CCPA. Additional ad-hoc privacy trainings are provided on 
an as needed basis.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
33
SUPPLIER MANAGEMENT
Our approach
We engage in reasonable due diligence to ensure compliance with all 
applicable laws during the supplier selection process. We screen our direct 
materials suppliers according to governing quality system standards, including 
compliance with the Modern Slavery Act of 2015. Additionally, no conflict 
minerals as defined by the Dodd-Frank Act are included in our product or 
manufacturing process.
To support economic empowerment, we seek relationships with suppliers 
owned by members of vulnerable, marginalized, or under-represented 
social groups, including businesses that are veteran owned, disabled owned, 
woman owned, LGBTQIA+, small disadvantaged, or operating in Historically 
Underutilized (HUB) zones.
Purchasing controls, including supplier service and quality agreements 
Suppliers, contractors, and consultants are assessed and selected on the basis 
of their ability to meet the requirements of the quality system and specific 
quality assurance requirements. All critical suppliers must sign a quality 
agreement, and suppliers are assessed, inspected, and audited on their ability 
to meet quality requirements.
HUMAN RIGHTS
Our approach
We have adopted several human rights policies or provisions that support our 
committment to our employees, patients, business partners, and communities. 
This includes policies prohibiting child labor, forced labor, discrimination, and 
harassment in the workplace.
The Modern Slavery provision within our Code of Business Conduct and Ethics 
states our commitment to ensuring no forced labor, modern slavery, or human 
trafficking occurs anywhere in our business or supply chains. Employees are 
obligated to report potential or suspected violations of laws prohibiting forced 
labor, modern slavery, or human trafficking by Exact Sciences, our personnel, or 
any of our suppliers to our Chief Compliance Officer or to our General Counsel.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
34
BOARD OVERSIGHT
Our Board of Directors provides oversight and 
receives updates on policies and risks associated 
with corporate governance and sustainability at least 
annually. 
These include: 
      ENVIRONMENTAL AND SOCIAL AFFAIRS
      LEGAL AND REGULATORY COMPLIANCE
      CLINICAL RESEARCH STANDARDS
      INFORMATION SECURITY
      DIVERSITY, EQUITY, AND INCLUSION
      PRODUCT QUALITY AND SAFETY
      CULTURE, TALENT, AND HUMAN CAPITAL
      PRODUCT DEVELOPMENT
      SHAREHOLDER FEEDBACK
      EXECUTIVE COMPENSATION
Sustainability is embedded within the activities of each of our board committees. 
Culture, talent, 
and human capital 
Diversity, equity, 
and inclusion 
Executive 
compensation
Environmental and 
social affairs
Legal and regulatory 
compliance
Product quality and 
safety
Product 
development
Laboratory and 
business operations
Information security
Legal and regulatory 
compliance
Product 
development
Clinical research 
standards 
INNOVATION, 
TECHNOLOGY, 
AND PIPELINE
CORPORATE 
GOVERNANCE AND 
NOMINATING
AUDIT AND 
FINANCE
HUMAN CAPITAL

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
35
ADDRESSING SHAREHOLDER FEEDBACK
During 2021, we implemented a proactive outreach program to 
gather feedback from our shareholders on environmental, social, 
and governance matters. We intend to continue our proactive 
and constructive shareholder engagement efforts going forward 
and to consider shareholder perspectives with respect to our ESG 
program and practices. During the summer and fall of 2021, we 
reached out to 30 of our top shareholders, collectively holding 
approximately 70% of our outstanding common shares. We held 
meetings with 9 of these shareholders, representing approximately 
25% of our outstanding common shares.
Katherine (Kay) Zanotti, Board member and Chair of the Human 
Capital Committee, led the shareholder engagement effort 
along with members of our management team, including 
representatives from finance, human resources, legal, and investor 
relations. The engagement meetings focused primarily on our 
executive compensation program. We also discussed our corporate 
strategy and environmental, social, and governance priorities that 
are important to our shareholders.  
We have made improvements in our environmental, social, and 
governance programs and disclosures to incorporate the valuable 
feedback we received from our shareholders, including:
Sustainability 
focus areas
Key feedback from 
shareholders
How we have responded
Environmental
Positive feedback on 
our efforts to date, 
would like to see more 
climate-related 
disclosures and targets
Established 2021 as our baseline year 
for reporting consolidated energy 
management, greenhouse gas 
emissions, and water usage data. 
Actively working to establish 
consolidated waste management data 
and plan to use 2022 as our baseline 
year for reporting.  
Social
Very positive views on 
our human capital 
efforts, gender diversity 
metrics well-received, 
would like other 
diversity metrics
Shared gender and ethnic/racial 
diversity metrics provided at the board 
of director, leadership, and total 
workforce levels for the first time. 
Governance
Constructive feedback 
on executive 
compensation, bonus 
philosophy, long-term 
incentive plans, and 
over-boarding policy
Our Human Capital Committee took 
several actions in 2021 based on 
shareholder feedback. Please see the 
next page for more details.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
36
ADDRESSING SHAREHOLDER FEEDBACK - GOVERNANCE
Key feedback from shareholders
How we have responded
Payouts under the short-term 
incentive plan should be based 
primarily on objective, pre-
determined targets
In 2021, our Human Capital Committee approved changes to our annual incentive bonus program to minimize discretion in favor of a
formulaic approach, which was reaffirmed in 2022.
More of the CEO’s compensation 
should be performance-based
In 2021, one-half of our CEO’s equity compensation was comprised of performance share units (PSUs), whereas in 2020 he did not receive 
any PSUs.
For the 2022 long-term incentive opportunity provided to our CEO, the Human Capital Committee determined to further increase the ratio 
of PSUs from 50% to 60%, with the remaining 40% delivered in the form of restricted share units (RSUs).
The Human Capital Committee approved the issuance of RSUs to Kevin Conroy, CEO, and Jeff Elliott, CFO and COO, in lieu of one-half of 
their base salary for 2022, per their request. The RSUs vest in 11 monthly installments from February 2022 through December 2022.
Additionally, and per their request, the Human Capital Committee approved the issuance of PSUs to Kevin Conroy and Jeff Elliott in lieu of 
one-half of their bonus opportunity for 2022. The amount of the PSUs that ultimately vest, if any, will be equal to the percentage of the 
bonus opportunity that is paid to bonus plan participants, based on the achievement of corporate goals established for such plan.
A greater percentage of long-
term incentives should be 
performance-based
In 2021, performance-based equity accounted for approximately 1/3 of long-term incentives for our executives, on average, and 50% of long-
term incentives for our CEO, which increased to 60% in 2022.
Effective 2021, we no longer grant time-based stock options as part of our long-term incentive mix.
Beginning with 2022 equity grants, the Human Capital Committee approved an increased use of performance-based equity awards 
subject to multi-year performance metrics. These are designed to reward long-term financial and scientific/product development 
performance aligned, with the interests of our shareholders.
Improve short- and long-term 
incentive programs description 
and transparency
Our 2021 proxy statement reflects enhanced disclosures to improve transparency and clarity around our compensation program design 
and payout determinations.
Continued integration of ESG 
goals into incentive plans
Our 2021 bonus plan continued to include a diversity metric, and the Human Capital Committee approved the addition of a mentorship 
objective to our 2022 bonus plan.
Performance metrics should 
closely align with shareholder 
interests
The Human Capital Committee added a profitability metric for the 2022 annual incentive plan and a total shareholder return modifier to 
the 2022 PSU program to more closely align incentives with our shareholders.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
37
CLINICAL RESEARCH
Our approach
We believe in generating high-quality scientific evidence during the development 
process to demonstrate the clinical utility of our tests. We have completed or are 
working on more than 220 clinical studies, generating evidence for tests that 
support patients before and throughout their cancer diagnosis and treatment.
Clinical study programs and standards
We have policies and procedures that govern and describe the ethics of 
conducting clinical studies at Exact Sciences, including topics such as obtaining 
informed consent, respect for potential and enrolled subjects, and fair subject 
selection, among others. 
Addressing diversity 
We have initiatives underway to help improve the diversity of enrollees in our 
clinical studies. We provide transportation services when needed, translated 
materials for research participants, and procedure coverage for the uninsured 
when appropriate. We also utilize Veterans Affairs and Federally Qualified Health 
Centers and increase accessibility with decentralized approaches in some 
studies. We updated our feasibility questionnaires to better understand site-level 
populations during site selection. We currently measure our demographics across 
active studies and have plans to enhance our future studies by diversifying patient 
populations through both study design and site selection. 
220+
160K+
6
completed & ongoing 
clinical studies
cumulative 
people enrolled
New England Journal of 
Medicine publications
Our scientific collaborations

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
38
CLINICAL RESEARCH 
PROGRAMS & STANDARDS
We design and conduct all clinical studies in accordance 
with the general principles set forth in the International 
Ethical Guidelines for Biomedical Research Involving 
Human Subjects (by the Council for International 
Organizations for Medical Sciences), USFDA Title 
21 CRF §11, 50, 54, 56, 812, & 814, the Declaration of 
Helsinki (World Medical Association) and ICH GCP E6 
(R2). Good Clinical Practice (GCP) is an international 
ethical and scientific quality standard that is provided 
by the International Council on Harmonization (ICH). 
Compliance with this standard provides public assurance 
that the rights, safety, and well-being of research 
participants are protected and that the clinical study 
data are credible.  
Additionally, every clinical study must be reviewed by 
national and/or regional regulatory authorities as well as 
independent local ethics committees (EC) or institutional 
review boards (IRB) in the countries where the study 
takes place. The purpose of the independent review 
is to ensure that risks for clinical study participants 
are responsibly managed and the risk to benefit ratio 
is as favorable as possible. The IRBs and ECs have the 
authority to approve, modify, or stop clinical studies.
For each clinical study executed by clinical affairs at Exact 
Sciences, a master Informed Consent Form template 
is required to be written following informed consent 
standards and, as applicable, in compliance with:
•	
Informed Consent Elements (76 FR 44512, July 26, 
2011)
•	
21 CFR 50. Protection of Human Subjects. pp. 340-352.
•	
DHHS FDA CDER CBER ICH. (2018). Guidance for 
Industry –E6 (R2) Good Clinical Practice: Integrated 
Addendum to ICH E6 (R1)
•	
Any other country-specific regulations (e.g., Health 
Canada) which may be applicable to the conduct of 
the clinical study
Following internal approval of the Informed Consent 
Form template, it is submitted to our central IRB for 
final approval before adoption. Consent templates also 
provide information regarding the rights of research 
participants. Consent forms provide relevant contact 
information in the event of a concern or complaint. Exact 
Sciences clinical studies are managed by the clinical 
affairs team. All employees on our clinical affairs team are 
required to take a clinical research ethics overview course 
and GCP training. We have an established Monitoring 
and Quality Audit System, which require the conduct of 
studies by investigator sites and contracted vendors to 
be observed by qualified clinical monitors. Separately, 
Exact Sciences does not undertake any animal testing or 
outsource any animal testing to any third party.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
39
CLINICAL RESEARCH DATA SHARING
The Exact Sciences Clinical Research Data Sharing Policy confirms the 
following:
 
Individual participant data that underlie the results reported in any 
publication of any Exact Sciences clinical study may be shared after 
deidentification. This may include text, tables, figures, and appendices. 
The study protocol, statistical analysis plan (when applicable), informed 
consent form (when applicable), and clinical study report (when 
applicable) may also be shared. 
Data may be available from two years and ending four years after 
publication. Data may be shared with researchers who provide a 
methodologically sound proposal to achieve the aims outlined in the 
approved proposal. 
Clinical studies are posted to public databases as required by law. Trial 
results, including the results of terminated trials where required, are 
published to clinicaltrials.gov.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
40
Our approach
We have a patient-focused culture where employees strive to deliver the highest quality 
health care. We are committed to meeting customer requirements and complying with 
applicable regulatory, laboratory accreditation, and Quality Management System (QMS) 
standards.
Our commitment to quality
Employees of Exact Sciences implement quality practices into every process by 
maintaining these key principles:
•	
Intently focusing on customer needs and expectations to provide value and ensure 
high satisfaction with all products and services
•	
Always promoting and sustaining continuous improvement in the efficiency and 
effectiveness of our quality and business processes
•	
Rigorously complying with laws and regulations pertaining to the quality, safety, and 
performance requirements in every country where our products and services are 
offered
Our Quality Policy is available here.
The Quality Policy extends to all contractors, sub-contractors, and temporary labor. 
Suppliers are required to comply with Good Manufacturing Practice (GMP) regulations, 
enforced by the U.S. Food and Drug Administration (FDA), and have their own Quality 
Policy, which is reviewed during qualification and subsequent monitoring (as described in 
our QMS).
PRODUCT QUALITY

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
41
QUALITY MANAGEMENT 
SYSTEM
Exact Sciences is committed to leading the industry with advanced science and quality product development. 
We fully comply with all regulations governing our technologies, from early discovery through product realization. 
Documentation of these practices is recorded and implemented within our QMS.
Exact Sciences’ QMS intends to assure our design, development, manufacturing, and distribution activities 
produce consistently high-quality products that meet or exceed our customers’ requirements. This is achieved 
through the preparation and effective implementation of documented procedures, instructions, and internal and 
external reviews. 
The Exact Sciences QMS provides guidance and best practices based on the current editions of:
•	
Food and Drug Administration (FDA) Code of Federal Regulations 21 CFR Part 820 – Quality System Regulation 
•	
ISO 13485, Medical Devices – Quality Management Systems
•	
EC Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices
Exact Sciences’ QMS is applied company-wide wherever work is being done to design, develop, produce, store, 
distribute, install, and/or service finished devices. The QMS is certified independently to global industry standards. 
While some certifications are not required by regulation, we embrace them as value-added, driving operational 
excellence.

All facilities that design, develop, produce, store, distribute, install, and/or service finished devices intended for 
human use are certified to the ISO 13485 (Medical Devices – Quality Management Systems) standard.
The objective of our quality policy, QMS, and all related processes and procedures is to identify potential hazards 
and minimize their risks.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
42
QUALITY MANAGEMENT 
SYSTEM PROGRAMS
Our product QMS includes, but is not limited to, the following responsibilities, 
procedures, instructions, and records:
Board and management responsibility
Our Audit and Finance Committee and our Board of Directors oversee quality 
management. Our CEO and Chief Laboratory Officer provide periodic updates 
on quality matters to our Board of Directors. Our Audit and Finance Committee 
receives an annual risk assessment covering risks associated with manufacturing, 
lab practices and performance, and compliance with quality requirements.
Our Chief Laboratory Officer is part of the executive leadership team and is 
responsible for implementing, maintaining, and reporting on the performance of 
the QMS. 
The management representative is responsible for:
•	
Ensuring that processes needed for the QMS are established, implemented, 
and maintained 
•	
Reporting to executive leadership on the performance of the QMS and any 
need for improvement
•	
Reviewing the suitability, adequacy, and effectiveness of the QMS with 
executive leadership through management reviews conducted at defined 
intervals
•	
Ensuring the promotion of awareness, training, and remediation of regulatory, 
quality, and customer requirements throughout the organization
•	
Chairing management review meetings, sending notifications to stakeholders 
and executive leadership, and documenting attendance and outcomes
Executive leadership reviews the organization’s QMS at least annually to ensure its 
continuing suitability, adequacy, and effectiveness. This review includes assessing 
opportunities for improvement and the need for changes to the QMS, including the 
Quality Policy and quality objectives. 
Exact Sciences’ employees, individually and collectively, are responsible for 
understanding, communicating, implementing, and maintaining the Quality 
System at all levels of the organization, and ensuring that the requirements of Exact 
Sciences’ QMS are fulfilled.
Quality audits
Each element of Exact Sciences’ QMS is audited internally by the Quality Lead 
Auditors at least once during a two-calendar year period.
External audits for ISO 13485 compliance are conducted every year. Our most 
recent ISO 13485 surveillance was conducted by BSI in December 2021, resulting 
in recommendation for continued certification. Regular FDA inspections to 21 CFR 
Part 820 – Quality System Regulation are conducted. Our fifth FDA audit was last 
completed in 2021 with no adverse findings.
Employee training
The product quality employee training program, governed by Exact Sciences’ 
Employee Training Policy, applies to all Exact Sciences employees, including full-time, 
part-time, and temporary employees who perform work responsibilities at Exact 
Sciences.
We offer 2,131 quality-pertinent courses and 17 computer-based training courses 
on a broad array of regulatory and compliance topics. There were 187,333 trainings 
completed by 6,339 employees in 2021, including 2,249 new employees. At a 
minimum, some aspects of GMP training are required annually.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
43
QUALITY MANAGEMENT 
SYSTEM
Risk management
A risk-based approach is applied to the QMS through appropriate procedures, throughout 
the product life cycle, from development through post-production. Product and process risk 
assessments are a requirement of the Risk Management Procedure. The Exact Sciences risk 
management procedure complies with the ISO 14971 (medical devices – application of risk 
management to medical devices) standard. ​
Product identification and traceability
Procedures are maintained for identifying each product by suitable means, starting from receipt, 
and during all stages of production and delivery.​
Production and process controls
Production and servicing processes which directly and indirectly affect product quality are identified 
and carried out under controlled conditions which may include, but are not limited to:​
•	
Documented procedures defining the manner of production, servicing, environmental 
conditions, and equipment maintenance​
•	
Compliance with reference standards/codes and quality activities which may affect product 
quality  ​
Activities include inspection and testing of incoming materials, in-process materials, and finished 
products.
Labeling and packaging controls​
Labeling and packaging control measures include: ​
•	
Handling, storage, and distribution of product​
•	
Safety data sheets for products accessed by patients 
Product monitoring ​
Procedures for implementation of corrective and preventive action throughout all operations 
affecting product quality include:​
•	
Feedback gathered from processes, work operations, quality audit reports, and complaints, or 
potentially reportable events, which may come from a variety of sources, including:
•  External – concerns received by customer support or service functions, journal articles, news 
media, direct communication via trade shows, regulatory bodies, meetings or sales contact with 
customer	 
•  Internal – product release testing or other evaluation, including trending, that suggests the 
product is not meeting established claims​
•	
Complaint handling procedures – the quality team reviews customer feedback, escalates relevant 
feedback through the complaints process, and provides, at a minimum, quarterly reports for 
management review; any protected confidential health information contained in quality records 
is subject to Exact Sciences’ Data Privacy Policy​
•	
Recalls and field action procedures – the recall and field action process consists of four phases: 
(1) preparation, (2) implementation, (3) follow-up, and (4) close-out; the implementation phase 
includes procedures for recall communications​
•	
Post-market surveillance​
Designated individuals are assigned responsibility for initiating, coordinating, documenting, and 
monitoring the corrective action process.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
44
CORRECTIVE & PREVENTIVE ACTION
As part of the Exact Sciences QMS, we have developed and maintain a 
dedicated Corrective and Preventive Action (CAPA) program, which confirms 
the procedures in the event of a product safety event.
The program provides a formalized method for:
•	
Analyzing processes, work instructions, concessions, quality audit reports, 
quality records, service records, complaints, returned product, and 
other sources of quality data to identify existing and potential causes of 
nonconforming product or other quality issues
•	
Investigating the cause of nonconformities or other quality issues relating to 
product, processes, and the quality system
•	
Identifying the action(s) needed to correct and prevent recurrence of 
nonconforming product and other quality issues
•	
Verifying or validating the corrective and preventive action to ensure that such 
action is effective and does not adversely affect the finished device
•	
Implementing and recording changes in methods and procedures needed to 
correct and prevent identified quality issues
•	
Ensuring that information related to quality issues or nonconforming product 
is disseminated to those directly responsible for assuring the quality of such 
product or the prevention of such issues
•	
Submitting relevant information on identified quality issues as well as 
corrective and preventive actions for management review
The program is overseen by the Quality Review Board, comprised of management 
representatives from quality, operations, and regulatory affairs. The Quality Review 
Board:
•	
Reviews and accepts or rejects CAPA requests
•	
Documents the rationale for CAPA rejection
•	
Appoints CAPA owners
•	
Approves CAPA plans, establishes the hazard and priority level of the identified 
problem, monitors the progress of open CAPAs, and approves closure when 
effectiveness checks have been successfully completed
All Exact Sciences employees, including part-time and temporary employees, are 
authorized to initiate CAPA requests. All potential adverse events are reviewed 
for reporting to the FDA under the Medical Device Reporting (MDR) regulation, 
and to competent authorities outside the U.S. in accordance with the respective 
reporting requirements. MDRs are publicly searchable (with certain exceptions, 
as confirmed on the MAUDE website) via the FDA Manufacturer and User Facility 
Device Experience (MAUDE) database. There have been no adverse events that 
would require Exact Sciences to submit an MDR since the beginning of 2021.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
45
ACCESS TO
HEALTH CARE
We relentlessly pursue smarter solutions providing the clarity to 
take life-changing action earlier, and our goal is to make our tests 
easily accessible to patients and health care professionals.
Our approach
We go above and beyond to make it easy and affordable to complete 
our tests.​ Our pursuit of smarter solutions providing the clarity to take 
life-changing action earlier is fueled by the success of Cologuard and 
Oncotype DX, our two leading product brands. ​

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
46
ACCESS TO TESTS
The Cologuard test is an accurate, non-invasive, patient-friendly screening test for the 
early detection of colorectal cancer and pre-cancer. It is the only FDA-approved, stool DNA 
screening option for colorectal cancer. Cologuard is indicated to screen adults 45 years 
of age and older who are at average risk for colorectal cancer by detecting certain DNA 
markers and blood in the stool. Cologuard is included in the American Cancer Society’s 
colorectal cancer screening guidelines and the recommendations of the U.S. Preventive 
Services Task Force (USPSTF) and National Comprehensive Cancer Network. In 2021, the 
USPSTF updated its colorectal cancer screening guidelines and lowered the recommended 
starting age for screening asymptomatic, average-risk patients from 50 to 45.​
Cologuard is covered by Medicare and most major commerical insurers. Today, 
approximately 95% of all Cologuard patients pay nothing out of pocket for screening. To 
achieve this, we pursued a variety of strategies to maximize commercial payer coverage, 
including the utilization of cost effectiveness data demonstrating the case for Cologuard 
reimbursement. Eligible patients who are actively enrolled in any State Medicaid program 
can access Cologuard.  No payment will be expected from the patient unless the plan 
requires a co-pay. We also have a patient support team providing informational resources 
to patients who have questions about Cologuard, including insurance coverage.​
The Oncotype portfolio of genomic tests provides physicians and patients with 
personalized insights about a patient’s tumor, allowing them to make treatment decisions 
with a greater degree of confidence.
Tailoring treatments to the individualized biology of each patient’s tumor has tremendous 
promise to improve outcomes for people with cancer, and the potential to reduce health 
care costs by eliminating unnecessary treatments.​
The landmark TAILORx and RxPONDER trials used the Oncotype DX Breast Recurrence 
Score test to define, with precision, the individual benefit of chemotherapy and distant 
rate of recurrence for early-stage breast cancer patients. For men diagnosed with low- or 
high-risk localized prostate cancer, the Oncotype DX Genomic Prostate Score (GPS) test 
measures the expression of certain genes in prostate cancer cells, combined with clinical 
factors, to help guide treatment decisions at the time of a patient’s diagnosis.
We also offer two therapy selection tests for patients with advanced or rare cancers. The 
Oncomap test delivers rapid, comprehensive tumor profiling to recommend targeted 
and immuno-therapies or clinical trials for patients with advanced, metastatic, refractory, 
relapsed, or recurrent cancer. The Oncomap ExTra test is a comprehensive genomic 
profiling test, including both whole-exome (DNA) and whole-transcriptome (RNA) 
sequencing across approximately 20,000 genes.

The Oncotype portfolio of tests are covered by Medicare and many commercial insurance 
plans and available to patients who are enrolled in a Medicaid program. 
Exact Sciences takes every viable step to make testing affordable, available, and 
accessible, and we offer financial assistance programs for eligible patients with financial 
hardship.​
Sources: ​Klein et al. Eur Urol. 2014​; Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7(283):283ra53. doi:10.1126/scitranslmed.aaa7161

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
47
In December 2021, Exact Sciences acquired PreventionGenetics, a genetic 
testing laboratory, to complement its advanced cancer diagnostics portfolio and 
support entrance into hereditary cancer testing. PreventionGenetics provides the 
clinical lab, expertise, and foundational technology necessary to accelerate the 
availability of hereditary cancer testing and help more patients understand their 
inherited risk of cancer to catch it earlier and treat it more effectively. 
PreventionGenetics is a CLIA-certified and CAP-accredited clinical DNA testing 
laboratory, providing more than 5,000 predefined genetic tests for nearly all 
clinically relevant genes, additional custom panels, and comprehensive germline 
whole exome and whole genome sequencing tests. With a goal to improve lives 
through genetic testing, PreventionGenetics offers tests spanning decades of 
life including proactive health and wellness, cancer risk and screening, pediatric 
and adult-onset rare diseases, and others. These high-quality genetic tests are 
supported by deep sequencing capabilities and more than 100 peer-reviewed 
publications.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
48
EDUCATING MORE PEOPLE ABOUT THE 
POWER OF EARLIER DETECTION
Black and Hispanic Americans are more likely to be diagnosed with 
colorectal cancer at later stages due in part to lower screening access. 
Exact Sciences launched the “Screening Has Meaning” campaign in 2021 to 
improve awareness of colorectal cancer screening for Black and Hispanic 
populations. We encouraged people to learn more about why screening matters, 
who should get screened, and how to get screened through radio and billboard 
advertisements in English and Spanish.
Source: American Cancer Society. Cancer Facts & Figures 2020; 
Wolf AMD, et al. CA Cancer J Clin. 2018
20% more likely 
to be diagnosed with colorectal cancer 
and are
Today, Black Americans are 
40% more likely 
to die from it.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
49
PARTNERING WITH STAND UP TO CANCER® 
TO RAISE COLORECTAL CANCER SCREENING 
AWARENESS
Public awareness campaign 
Exact Sciences is partnering with Stand Up to Cancer (SU2C®) to help improve 
colorectal cancer screening rates and increase early detection and prevention 
across America. 
Exact Sciences provided a $10 million grant, funding the SU2C PSA campaign 
featuring Academy Award® winner, Jamie Foxx, which launched in March of 2021. 
In 2021, the Jamie Foxx SU2C PSA aired on television 127,354 times to a potential 
audience of 782 million people, as well as 71,389 radio airings with 307 million gross 
impressions.
The new Dream Team 
Our grant also helped create a colorectal cancer “Dream Team” of researchers. 
The team is focused on providing free colorectal cancer screenings to community 
health clinics in at-risk minority and medically underserved communities. The 
team’s research will aim to develop better approaches to colorectal cancer 
screening, starting in Milwaukee, Los Angeles, Boston, and South Dakota.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
50
COLOGUARD CLASSIC
Every year, Exact Sciences sponsors the Cologuard Classic golf tournament in Tucson, Arizona as 
part of the PGA TOUR Champions. It’s one of the primary ways Exact Sciences raises awareness 
of colorectal cancer and the importance of screening. It’s also an opportunity to bring colorectal 
cancer advocacy groups, patients, survivors, and caregivers together to celebrate progress made 
fighting colorectal cancer and discuss ways to do even more. 
More than 100 colorectal cancer patients, survivors, and caregivers participated virtually or in 
person in what has become one of the most unique and powerful events on the PGA TOUR 
Champions. Fourteen survivors, patients, and caregivers played in the pro-am, golfing alongside 
players competing in the tournament.
All 81 professional golfers in the field competed on behalf of a colorectal cancer patient, survivor, 
or caregiver. The players wore ribbons that included the name of the honoree they represented. 
Ten of the nation’s leading colorectal cancer advocacy groups nominated individuals to 
participate.	
 
The tournament also raised $50,000 in donations for colorectal cancer screening and awareness 
initiatives in the Tucson area. In its fourth year with Exact Sciences as the title sponsor, the 
Cologuard Classic has quickly evolved into a major event in the advocacy community.
THE COLOGUARD CLASSIC’S MISSION: 
RAISE AWARENESS OF THE IMPORTANCE OF EARLY 
DETECTION OF COLORECTAL CANCER THROUGH 
SCREENING AND RECOGNIZE THOSE THAT HAVE 
BEEN AFFECTED BY THE DISEASE.
IMPACT ON PATIENTS – SCOTT’S STORY
At 53 years old, Scott had a list of reasons he put off screening for colon cancer. He was worried about 
the bowel prep and invasive nature of a colonoscopy. Scott also felt healthy and took care of himself 
by exercising and eating right, so he didn’t understand why he needed to prioritize screening.
In February 2020, Scott attended the Cologuard Classic in Tucson, Arizona, where he learned about 
Cologuard. He liked that Cologuard was an easy test he could use at home, allowing him to get 
screened without taking time out of his busy schedule for an invasive procedure.
During a routine visit to his health care professional, Scott and his doctor decided Cologuard was the 
right screening option for him. Scott felt comfortable using Cologuard because he could complete 
the test from the safety of his own home amidst the COVID-19 pandemic. He received a positive 
result from his Cologuard test, and during his follow-up colonoscopy, a tumor was found. After 
having surgery, Scott found out it was stage I colon cancer. He recalls the days following surgery as 
some of his hardest, as he worried what his diagnosis meant for himself and his family.
Scott underwent treatment for his cancer and at a follow-up appointment several months later, his 
doctor found no signs of disease. Now, he’s back doing what he loves: golfing, hiking, and spending 
time with friends and family. Scott has made it his personal mission to encourage others to get 
screened when they’re eligible, and believes if he can help just one person, it’s all worth it.
Screening with Cologuard 
changed the course of 
my life. The work Exact 
Sciences does matters so 
much to people – thank 
you for what you do.
— Scott“

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
51
Our approach
We recognize the science supporting the need for climate change and understand all
companies can play a greater role in creating a better, more sustainable planet. We are
committed to operating our businesses and facilities and to producing our products in a
manner that respects and protects human health and the environment. Our Environmental
Policy is embedded in our Code of Business Conduct and Ethics, and applies to all of our
global locations.
Our Environmental Management System
We have dedicated environmental resources that work closely with all business units and
functions to establish and implement environmental programs and policies. We require all
operations to maintain compliance with national, regional, and local regulations relating to
the environment, such as those affecting air emissions, water purity, and waste disposal. To
decrease our impact on the environment, we have made significant investments in energy
efficiency, recycling, and water conservation programs. Many of these investments and
associated improvements have been recognized externally as best-in-class achievements.
ENVIRONMENTAL 
STEWARDSHIP

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
52
ENERGY MANAGEMENT
GREENHOUSE GAS EMISSIONS
Our approach
We established consolidated energy data management and reporting 
in 2021, and plan to use 2021 as our baseline year for ongoing progress 
measurement. To date, we have focused on the following energy efficiency 
opportunities:
•	
Automation control system optimizations
•	
High efficiency motors, chillers, boilers, and other mechanical equipment
•	
Primary/secondary pumping systems
•	
Heat recovery systems
•	
Variable speed drives and pumping
•	
Geothermal
•	
LED lighting, daylight harvesting, and advanced lighting controls
•	
LEED certification programs
Our approach
Our goal is to operate and produce our products in a sustainable 
manner which minimizes our impact on the environment. We have 
and will continue to upgrade our infrastructure and processes to 
make them more sustainable.​
For the first time, we are voluntarily reporting our GHG emissions, 
with 2021 as our baseline year. Our reporting is aligned with the 
GHG Protocol Corporate Standard on an operation control basis 
to provide consistency and transparency, and include Scope 
1 (Stationary Combustion and Mobile Sources) and Scope 2 
(Purchased and Consumed Electricity).
Note: GHG emissions calculated using EPA SGEC V7 tool and include 
metered sources for owned property and operating leases with 100% control.  
Note: total electricity and gas consumed include metered 
sources for owned property and operating leases with 100% control.
2021
Total (mtCO2e)
Scope 1: stationary combustion
3,319
Scope 1: mobile sources
8,712
Scope 2: purchased electricity
13,221
Total GHG emissions
25,251
2021
Total (mtCO2e)
2021
Total electricity consumed (kWh)
22,589,724
Total gas consumed (therms)
624,860
Total energy usage (MMBTU)
139,562
Total electrical renewable energy
22.3%
Total renewable energy
12.3%
2021

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
53
ASHRAE TECHNOLOGY AWARD
In October 2021, our Discovery Campus Lab in Madison, Wisconsin 
was selected to receive a First Place ASHRAE Technology Award. 
The ASHRAE Technology Awards program recognizes outstanding 
achievement in the design and operation of energy efficient buildings. 
The project achieved 39% energy reduction versus the LEEDv4 ASHRAE 
90.1-2010 Appendix G baseline, and metered kBtu/SF/yr data is 50% less 
than the ASHRAE climate zone 6, “Labs for the 21st Century” benchmark. 
Innovative energy reduction design elements:​
•	
Energy and water metering throughout the building to capture 
major end uses and allow for monitoring and improvement
•	
Water modeling showing that 98% of flush fixtures and site irrigation 
usage is offset via rainwater harvesting and reuse system
•	
Blower coil units manage the sensible load for equipment-driven 
spaces, which achieves the intent and energy performance of chilled 
beams while avoiding water piping above critical equipment
Key energy conservation measures contributed to significant savings 
in the final design including:

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
54
WATER MANAGEMENT
Our approach
We established consolidated water usage data management and reporting 
in 2021, and plan to use 2021 as our baseline year for ongoing progress 
measurement. To date, we have focused on water reduction and recycling 
opportunities including:​
•	
Low flow fixtures
•	
Leak detection systems
•	
Water reclamation
•	
Rainwater capture
In 2021, our Madison, Wisconsin locations achieved 2021 Climate Champion 
recognition for our water conservation and innovative recycling solutions 
including: 
•	
Actively managing our water softeners and winter salt use to reduce 
chloride in local lakes​
•	
Implementing a water softener brine recovery system
•	
Installing a new clinical lab waste processing and recycling system that 
uses 90% less water than the previous system
2021
Total water usage* (gals)
12,566,331
*Note: 28% of total water usage is estimated based on square footage 
and space type for unmetered locations.
2021
WASTE MANAGEMENT
Our approach
We have established waste disposal guidelines and training to ensure proper 
categorization, disposal, and recycling of waste streams. We are actively working to 
establish consolidated waste data and reporting, and plan to use 2022 as our baseline 
year for ongoing progress measurement. 

To date, we have focused on waste management, reduction, and recycling 
opportunities including:
•	
Recycling nearly 80% of our hazardous waste associated with our Cologuard 
sample collection and testing processes, which equates to more than 95,000 
pounds of waste diverted from landfill
•	
Recycling lab wastes including cardboard, styrofoam, gloves, and masks
•	
Switching to reusable and/or compostable dishware
•	
Installing biodigesters for aerobic digestion in our large kitchen facilities
•	
Implementing a process to decontaminate and recycle Cologuard plastic lab 
waste; information on this system can be found here

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
55
APPENDIX

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
56
EXACT SCIENCES 2021 SUSTAINABILITY ACCOUNTING STANDARDS
The following tables provide data and information for Exact Sciences utilizing the Sustainable Accounting Standards Board (SASB) Health 
Care Delivery standard, which we believe best represents the nature of Exact Sciences’ operations. We also include indicators from the 
Biotechnology and Pharmaceuticals standard. The data represents full-year 2021 performance.
Category
Code
Accounting Metric
Information
Energy 
Management
HC-DY-130a.1
(1) Total energy consumed, (2) percentage grid
electricity, (3) percentage renewable
(1) 22,589,724 kWh of electricity, 624,860 therms of natural gas
(2) 77.7%
(3) 22.3%
Waste 
Management 
HC-DY-150a.1
Total amount of medical waste, percentage (a)
incinerated, (b) recycled or treated, and (c)
landfilled
Not reported
For more information, see: Waste Management
HC-DY-150a.2
Total amount of: (1) hazardous and (2) nonhazardous 
pharmaceutical waste, percentage
(a) incinerated, (b) recycled or treated, and (c)
landfilled
Not reported
For more information, see: Waste Management
Patient Privacy & 
Electronic Health 
Records
HC-DY-230a.1
Percentage of patient records that are
Electronic Health Records (EHR) that meet
"meaningful use" requirements
Not reported
For more information, see: Cybersecurity and Data Protection Risk 
Management
HC-DY-230a.2
Description of policies and practices to secure
customers’ protected health information (PHI)
records and other personally identifiable
information (PII)
We have technical, administrative, and physical safeguards in place to 
help protect against unauthorized access to, use, or disclosure of patient 
and employee information and data we collect and store
For details, see: Cybersecurity and Data Protection Risk Management
HC-DY-230a.3
(1) Number of data breaches, (2) percentage
involving (a) personally identifiable information
(PII) only and (b) protected health information
(PHI), (3) number of customers affected in
each category, (a) PII only and (b) PHI2
Not reported
For more information, see: Cybersecurity and Data Protection Risk 
Management
HC-DY-230a.4
Total amount of monetary losses as a result of
legal proceedings associated with data security
and privacy
Material legal, regulatory, and monetary issues are disclosed in our 
annual 10-K and quarterly 10-Qs

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
57
EXACT SCIENCES 2021 SUSTAINABILITY ACCOUNTING STANDARDS
Category
Code
Accounting Metric
Information
Access for Low-
Income Patients
HC-DY-240a.1
Discussion of strategy to manage the mix of patient 
insurance status
Exact Sciences takes every viable step to make testing affordable, available, and 
accessible, and we offer financial assistance programs for eligible patients 
with financial hardship
For details, see: Access to Tests
HC-DY-240a.2
Amount of Medicare Disproportionate Share Hospital (DSH) 
adjustment payments received
Not applicable – Exact Sciences provides laboratory testing services
Quality of Care & 
Patient Satisfaction
HC-DY-250a.1
Average Hospital Value-Based Purchasing Total Performance 
Score and domain score, across all facilities
Not applicable – Exact Sciences provides laboratory testing services
HC-DY-250a.2
Number of Serious Reportable Events (SREs) as defined by 
the National Quality Forum (NQF)
Not reported
HC-DY-250a.3
Hospital-Acquired Condition (HAC) Score per Hospital
Not applicable – Exact Sciences provides laboratory testing services
HC-DY-250a.4
Excess readmission ratio per hospital
Not applicable – Exact Sciences provides laboratory testing services
HC-DY-250a.5
Magnitude of readmissions payment adjustment as part of 
the Hospital Readmissions Reduction Program (HRRP)
Not applicable – Exact Sciences provides laboratory testing services
Management of 
Controlled 
Substances
HC-DY-260a.1
Description of policies and practices to manage the number 
of prescriptions issued for controlled substances
Not applicable – Exact Sciences provides laboratory testing services
HC-DY-260a.2
Percentage of controlled substance prescriptions written for 
which a prescription drug monitoring program (PDMP) 
database was queried
Not applicable – Exact Sciences provides laboratory testing services
Pricing & Billing 
Transparency
HC-DY-270a.1
Description of policies or initiatives to ensure that patients are 
adequately informed about price before undergoing a 
procedure
Not applicable – Exact Sciences provides laboratory testing services
For details, see: Access to Health Care
HC-DY-270a.2
Discussion of how pricing information for services 
is made publicly available
We have a Patient Support Team providing informational resources to patients who 
have questions about our products and services, including insurance coverage 
For details, see: Access to Tests
HC-DY-270a.3
Number of the entity’s 25 most common services for which 
pricing information is publicly available, percentage of total 
services performed (by volume) that these represent
Not reported

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
58
EXACT SCIENCES 2021 SUSTAINABILITY ACCOUNTING STANDARDS
Category
Code
Accounting Metric
Information
Employee Health 
& Safety
HC-DY-320a.1
(1) Total recordable incident rate (TRIR) and (2) days away,
restricted, or transferred (DART) Rate
(1) 0.62 per 200,000 hours worked
(2) 0.47
Employee 
Recruitment, 
Development & 
Retention
HC-DY-330a.1
(1) Voluntary and (2) involuntary turnover rate for: (a)
physicians, (b) non-physician health care practitioners, and
(c) all other employees
Not reported
HC-DY-330a.2
HC-BP-330a.1
Description of talent recruitment and retention
efforts for health care practitioners
We are committed to providing safe and healthy work environments 
for our employees, where equal opportunity and diversity in thought, 
experience, perspective, and background are commonplace; note, we 
do not employ health care providers
For details, see: Human Capital
Climate Change 
Impacts on Human 
Health & 
Infrastructure
HC-DY-450a.1
Description of policies and practices to address: (1) the 
physical risks due to an increased frequency and intensity of 
extreme weather events and (2) changes in the morbidity and 
mortality rates of illnesses and diseases, associated with 
climate change
For details, see: TCFD Disclosure
HC-DY-450a.2
Percentage of health care facilities that comply with the 
Centers for Medicare and Medicaid Services (CMS) Emergency 
Preparedness Rule
Not applicable – Exact Sciences provides laboratory testing services
Fraud & 
Unnecessary 
Procedures
HC-DY-510a.1
Total amount of monetary losses as a result of legal 
proceedings associated with Medicare and Medicaid fraud 
under the False Claims Act
Material legal and regulatory issues are disclosed in our annual 10-K and 
quarterly 10-Qs 
Ethics
HC-BP-270a.2
Description of code of ethics governing promotion of off-label 
use of products
Employees involved in sales and marketing receive regular compliance 
training on the laws, regulations, and codes that govern interactions with 
physicians and other customers, on the promotion of our products, and 
on our Code of Business Conduct and Ethics
For details, see Business Ethics
HC-BP-510a.2
Description of code of ethics governing interactions with 
health care professionals 
See our Code of Conduct on Interactions with Health Care Professionals

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
59
EXACT SCIENCES 2021 SUSTAINABILITY ACCOUNTING STANDARDS
Category
Code
Accounting Metric
Information
Safety of Clinical 
Trial Participants 
HC-BP-210a.1 
Discussion, by world region, of management process for 
ensuring quality and patient safety during clinical trials
We design and conduct all clinical studies in accordance with the 
general principles set forth in the International Ethical Guidelines for 
Biomedical Research Involving Human Subjects (by the Council for 
International Organizations for Medical Sciences), USFDA Title 21 CRF §11, 
50, 54, 56, 812, & 814, the Declaration of Helsinki (World Medical 
Association), and ICH GCP E6 (R2) 
For details, see: Clinical Research Programs & Standards
Activity Metrics
HC-DY-000.A
Number of (1) facilities and (2) beds, by type
Not applicable – Exact Sciences provides laboratory testing services
HC-DY-000.B
Number of (1) inpatient admissions and (2) outpatient visits
Not applicable – Exact Sciences provides laboratory testing services
HC-BP-000.A
Number of patients treated
As of 2021, we screened more than 7.5 million patients with Cologuard 
and nearly 1.5 million patients with Oncotype. We also completed more 
than 3.7 million COVID-19 tests
For details, see: Taking Care of the People We Serve
HC-BP-000.B
Number of drugs (1) in portfolio and (2) in research and 
development (Phases 1-3)
Not applicable – Exact Sciences provides laboratory testing services
(1) See Our Tests on our website to learn more
(2) See Our Pipeline & Data on our website to learn more

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
60
EXACT SCIENCES 2021 TASK FORCE ON CLIMATE-RELATED FINANCIAL DISCLOSURES (TCFD) INDEX
We strive to provide transparency on our climate change risk management. The TCFD has developed voluntary, consistent climate-related 
financial risk disclosures for use by companies in providing information to stakeholders, which we have used to guide our reporting.
Governance
a) Board oversight
Our Board of Directors provides oversight of sustainability, including climate-change related issues, and receives updates on associated policies and risks at least annually. 
Specific oversight of environmental issues is the responsibility of the Corporate Governance and Nominating Committee, which reviews the company’s principles, 
programs, and practices on sustainability topics, including those related to climate change.
Our senior managers and executives brief the full Board annually regarding the results of our annual enterprise risk assessment, including risks related to climate change, 
and annually reviews our business continuity planning, which is affected by climate change-related issues, with the Audit Committee. Our senior managers and 
executives will also brief the Board and its committees, as needed, throughout the year on issues directly and indirectly related to climate change. 
b) Management role
Our CEO and other leaders have executive oversight of our approach to environmental matters, including climate and energy. The executive team regularly discusses 
product development and innovation, including the environmental impacts of current and future products.
We have dedicated environmental resources that work closely with all business units and functions to establish and implement environmental programs and policies, and 
require all operations to maintain compliance with national, regional, and local regulations relating to the environment, such as those affecting air emissions. To decrease 
our impact on the environment, we have made investments in energy efficiency, including the use of renewables, among other actions. Our environmental policy is 
embedded in our Code of Business Conduct and Ethics and applies to all global locations.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
61
EXACT SCIENCES 2021 TASK FORCE ON CLIMATE-RELATED FINANCIAL DISCLOSURES (TCFD) INDEX
Strategy
a) Climate-related risks
While we believe that climate change-related issues pose minimal material risk to our business, we have identified climate-related risks that may affect us over the short-, 
medium-, and longer-term. These include:
•
Physical risks: extreme weather, including the possibility of flooding or other weather-related damage, may impact our operations and the ability of our employees to 
reach our physical locations. This same weather may also impact patients, medical practices, and other providers (who are our customers).
•
Regulatory risks: although we are not a significant user of energy or emitter of greenhouse gases, regulations to limit climate change may lead to increases in certain  
operating and commodity costs.
b) Impact on strategy
Our leadership team is committed to considering the potential risks and opportunities climate change may pose to our business. Exact Sciences regularly evaluates ways 
to reduce the resource needs of our operations, and the direct and indirect environmental impacts of the supply, manufacturing, use, and disposal of our products. 
We recognize that all companies must play a role in creating a better, more sustainable planet. We are committed to operating our businesses and facilities and 
producing our products in a manner that respects and protects human health and the environment.
c) Climate resilience
Our senior managers and executives monitor changing regulatory requirements and other impacts to our business. Our goal is to operate and produce our products in a 
sustainable manner which minimizes our impact on the environment. Our energy management approach has focused on efficiency opportunities such as automated 
control system optimization, high efficiency equipment, and heat recovery systems. This allows us to operate efficiently while reducing our energy usage.
Risk Management
Our leadership team and Board of Directors are focused on effectively managing our strategic and business risks, including climate change-related risks. The process to 
identify, manage, and integrate climate risk is embedded in our standard risk management approach. We identify, monitor, assess, and communicate these risks to help 
inform our operating and investment decisions. Our Board of Directors administers its risk oversight function directly and through various board committees, regularly 
discussing the company’s major risk exposures and risk management activities, including precautionary plans for disaster protection.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
62
EXACT SCIENCES 2021 TASK FORCE ON CLIMATE-RELATED FINANCIAL DISCLOSURES (TCFD) INDEX
Metrics
a) Metrics
We established consolidated energy data management and reporting in 2021, and plan to use 2021 as our baseline year for ongoing progress measurement.
We are voluntarily reporting our GHG emissions for the first time this year, which will set 2021 as our baseline. Our reporting is aligned with the GHG Protocol Corporate 
Standard on an operation control basis to provide consistency and transparency and include Scope 1 (Stationary Combustion and Mobile Sources) and Scope 2 (Purchased 
and Consumed Electricity).
b) Scope 1 and Scope 2 GHG emissions*
Scope 1 emissions (2021): 
•
stationary combustion – 3,319 mt CO2e
•
mobile sources – 8,712 mt CO2e
Scope 2 emissions (2021): 
•
purchased electricity - 13,221 mt CO2e
*GHG emissions calculated using EPA SGEC V7 tool and include metered sources for owned property and operating leases with 100% control. 
c) Targets
Exact Sciences is evaluating a carbon reduction goal now that it has completed its first GHG inventory.

2021 ESG REPORT
HUMAN CAPITAL
COMMUNITY ENGAGEMENT
BUSINESS ETHICS
ACCESS TO HEALTH CARE
ENVIRONMENTAL STEWARDSHIP
PRODUCT QUALITY
63
Cologuard is a registered trademark of Exact Sciences 
Corporation in the U.S. and other countries. Oncotype, Oncotype 
DX, Breast Recurrence Score, Genomic Prostate Score, GPS, and 
Oncomap are trademarks of Genomic Health, Inc. in the U.S. and 
other countries.
Investor Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
Media Contact:
Katie Boyce
Exact Sciences Corp.
kboyce@exactsciences.com
608-710-3903
Exact Sciences Corporation |  5505 Endeavor Lane | Madison, WI 53719
©2021 Exact Sciences Corporation. All rights reserved.